Cagrilintide is a newer name in the weight-loss world, often mentioned next to drugs like semaglutide (you'll also see it misspelled as "cagrilinitide"). It's a genuinely interesting idea that's being tested in real human trials — but it's not an approved medicine yet, and that's an important difference.

What cagrilintide actually is

Cagrilintide is a man-made peptide designed to copy a natural hormone called amylin. Your body releases amylin when you eat; it helps you feel full and slows how fast food leaves your stomach. A copy of amylin like cagrilintide is called an "amylin analog." The idea is that by mimicking amylin, it can help curb appetite and support weight loss.

What it's studied for

Cagrilintide is being studied mainly for:

  • Weight loss and helping people feel full sooner
  • Curbing appetite by copying the amylin 'fullness' signal
  • Working together with semaglutide as a combination called 'CagriSema'

The 'CagriSema' combination — cagrilintide plus semaglutide — is the version getting the most attention, because pairing two different appetite signals may work better than one.

Does cagrilintide actually work?

Unlike some peptides that only have animal data, cagrilintide is actually being tested in human clinical trials — large, randomised, placebo-controlled ones — and early results have looked promising for weight loss. But 'promising in trials' is not the same as 'proven and approved.' Trials are still ongoing, the full safety picture is still being built, and no regulator has approved it yet. So it sits in the honest middle: real human research, no final green light.

The estimated mean percent change in body weight from baseline to week 68 was -20.4% with cagrilintide-semaglutide as compared with -3.0% with placebo (estimated difference, -17.3 percentage points; 95% confidence interval, -18.1 to -16.6; P<0.001).

New England Journal of Medicine, 2025 (PMID 40544433)

That's the REDEFINE 1 trial, and it's a genuinely strong result. It's also a result for the *combination*, produced in a monitored trial with the real trial medicine — not for a vial bought online.

Is cagrilintide approved yet?

No. Cagrilintide is investigational, which means it's still working its way through clinical trials and hasn't been cleared by the FDA or other major regulators. It can't legally be sold as a treatment. Anything advertised online as cagrilintide is not the trial drug and hasn't been through any of the checks that make an approved medicine an approved medicine.

What the research points to

  • Promising early human-trial results for weight loss
  • A sensible scientific idea — copying the amylin 'fullness' hormone
  • Extra interest when paired with semaglutide as 'CagriSema'

What it does NOT prove

  • That it's a proven, approved weight-loss medicine
  • That its long-term safety in people is fully established
  • That 'research chemical' versions online are the real, quality-checked drug

Who talks about it — and why to be careful

Cagrilintide is popular in weight-loss and biohacking discussions, riding the wave of interest in drugs like semaglutide and tirzepatide. Remember that it's still investigational — the people using it safely are volunteers in monitored clinical trials, not people buying vials online. If you're looking at weight-loss options, a qualified doctor can point you to treatments that are actually approved and monitored.

What this does not mean

  • This does not mean cagrilintide is a proven or approved weight-loss medicine — it's still in clinical trials.
  • This does not mean it's safe to buy and inject; unregulated products aren't the trial drug and aren't checked for purity or safety.
  • This is general education, not medical advice or a recommendation to use cagrilintide.